Cholangiocarcinoma Therapeutics

A Global Strategic Business Report

MCP26833

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

6947

EXECUTIVE POOL

5850

PRICE

809

EXPERT INPUTS

44

COMPANIES

108

DATA TABLES

182

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Cholangiocarcinoma Therapeutics Market to Reach US$962.0 Million by 2030

The global market for Cholangiocarcinoma Therapeutics estimated at US$878.8 Million in the year 2024, is expected to reach US$962.0 Million by 2030, growing at a CAGR of 1.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$592.5 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 0.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$232.1 Million While China is Forecast to Grow at 1.3% CAGR

The Cholangiocarcinoma Therapeutics market in the U.S. is estimated at US$232.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$153.2 Million by the year 2030 trailing a CAGR of 1.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.4% CAGR.

Global Cholangiocarcinoma Therapeutics Market - Key Trends and Drivers Summarized

Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts. The disease is often diagnosed at an advanced stage due to its asymptomatic nature in the early phases, which complicates treatment and worsens prognosis. Standard treatment options for cholangiocarcinoma include surgery, chemotherapy, and radiation therapy. Surgery, particularly resection, offers the best chance for a cure, but it is only feasible in a minority of patients due to the late presentation of the disease. For unresectable or metastatic cases, chemotherapy regimens typically include combinations such as gemcitabine with cisplatin, although these treatments primarily aim to prolong survival rather than cure the disease. Recently, the advent of targeted therapies and immunotherapies has provided new avenues for treatment, giving hope to patients with advanced cholangiocarcinoma.

The landscape of cholangiocarcinoma therapeutics has been significantly transformed by advances in molecular biology and genetics, leading to the development of targeted therapies. These therapies are designed to attack specific genetic mutations or alterations that drive cancer growth. For instance, FGFR2 (fibroblast growth factor receptor 2) fusions and IDH1 (isocitrate dehydrogenase 1) mutations are found in a subset of cholangiocarcinoma patients and have become targets for novel drugs. Pemigatinib and infigratinib, both FGFR inhibitors, have shown efficacy in clinical trials, offering new treatment options for patients with FGFR2 fusions. Similarly, ivosidenib, an IDH1 inhibitor, has demonstrated benefits for patients with IDH1-mutant cholangiocarcinoma. Immunotherapy, particularly checkpoint inhibitors like pembrolizumab, is also being explored, although the response rates in cholangiocarcinoma have been modest compared to other cancers. Ongoing clinical trials are investigating combinations of these therapies to enhance their effectiveness and overcome resistance mechanisms.

The growth in the cholangiocarcinoma therapeutics market is driven by several factors. The increasing incidence of cholangiocarcinoma, partly attributed to rising rates of liver diseases and infections such as hepatitis B and C, is expanding the patient population in need of treatment. Technological advancements in genomic profiling and personalized medicine are facilitating the identification of actionable mutations, thereby driving the development and adoption of targeted therapies. Furthermore, substantial investment in research and development by pharmaceutical companies is leading to a robust pipeline of novel therapeutics. Regulatory support and expedited approval processes for orphan drugs are also propelling market growth, as these incentives encourage the development of treatments for rare diseases like cholangiocarcinoma. Additionally growing awareness among healthcare professionals and patients about the potential of targeted and combination therapies is boosting demand. As these trends continue to evolve, the cholangiocarcinoma therapeutics market is poised for significant expansion, driven by technological advancements, a deeper understanding of cancer biology, and a strong focus on innovative treatment strategies.

SCOPE OF STUDY

The report analyzes the Cholangiocarcinoma Therapeutics market by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Other Therapies); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

Bold Therapeutics; CStone Pharmaceuticals; Genfit SA; J-Pharma Co., Ltd.; Lisata Therapeutics; Owkin, Inc.; RedHill Biopharma Ltd.; RenovoRx, Inc.; Servier Laboratories; Specialised Therapeutics Australia Pty Limited; Taiho Pharmaceutical Co., Ltd.; Tempest Therapeutics; TriSalus Life Sciences; Tyra Biosciences;

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

Global Economic Update

Cholangiocarcinoma Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 86 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Increasing Incidence of Cholangiocarcinoma Expands Addressable Market Opportunity

Advances in Genomic Profiling Propel Development of Targeted Therapies

Rising Rates of Liver Diseases and Hepatitis Infections Drive Demand for Treatments

Technological Innovations in Personalized Medicine Strengthen Business Case for Novel Therapies

Growing Awareness of Targeted and Combination Therapies Accelerates Market Adoption

Identification of Actionable Genetic Mutations Throws Spotlight on Precision Medicine

Increasing Use of FGFR and IDH1 Inhibitors Drives Market Expansion

Exploration of Immunotherapy Combinations Generates New Opportunities

Challenges in Early Diagnosis and Late-Stage Presentation Propel Need for Advanced Therapeutics

Integration of Biomarker Testing in Treatment Planning Enhances Efficacy

Rising Healthcare Expenditure Expands Reach of Therapies

Focus on Overcoming Resistance Mechanisms Sustains Growth in Therapeutic Development

Adoption of Precision Oncology Approaches Drives Development of Personalized Therapies

4. GLOBAL MARKET PERSPECTIVE

World Cholangiocarcinoma Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Cholangiocarcinoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Cholangiocarcinoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

JAPAN

Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

CHINA

Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

EUROPE

Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Europe Historic Review for Cholangiocarcinoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Cholangiocarcinoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

FRANCE

Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

GERMANY

Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

UNITED KINGDOM

Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2015, 2025 & 2030

Rest of World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Bold Therapeutics	%
CStone Pharmaceuticals	%
J-Pharma Co., Ltd.	%
Lisata Therapeutics	%
Owkin, Inc.	%
RedHill Biopharma Ltd.	%
RenovoRx, Inc.	%
Servier Laboratories	%
Specialised Therapeutics Australia Pty Limited	%
Taiho Pharmaceutical Co., Ltd.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll